Cereno’s CEO: “very excited for topline readout!”
Cereno Scientific has released its Q2 report for 2024, highlighting the company’s advancements in developing cardiovascular disease treatments. CEO Sten R Sörensen came by the BioStock Studio to discuss the main takeaways from the period and take a sneak peak into what’s to come for the company during Q3.
Watch the interview with Cereno Scientific’s CEO Sten R Sörensen below:
